Table 2.
Clinical characteristics
| P value | Control Group (N=20) | POR Group (N=20) | Variable |
|---|---|---|---|
| Age (Y) | 30.47 ± 4.62 | 30.75 ± 3.89 | 0.727 |
| BMI (kg/m2), | 25.87 ± 2.92 | 25.20 ± 4.19 | 0.55 |
| Duration of infertility (Y) | 9.76 ± 6.04 | 7.70 ± 5.41 | 0.25 |
| Menstrual type, n (%) | |||
| Regular | 20 (100) | 20 (100) | |
| Irregular | 0 | 0 | |
| LH (mU/ml) | 4.23 ± 2.24 | 5.02 ± 3.39 | 0.38 |
| FSH (mU/ml) | 10.99 ± 3.24 | 8.55 ± 5.37 | 0.08 |
| LH/FSH ratio | 0.56 ± 0.92 | 0.64 ± 0.33 | 0.71 |
| Testosterone (ng/ml) | 1.21 ± 0.31 | 1.31 ± 0.54 | 0.33 |
| AMH (ng/ml) | 0.175 ± 0.03 | 0.63 ± 0.18 | 0.02 |
| No. of mature oocyte | 1.5 ± 0.44 | 10.1 ± 1.59 | 0.00 |
| Total rFSH dose (IU) | 3321 ± 243.65 | 2390.3 ± 190.39 | 0.005 |
Presented as mean ± SD and compared by t test.
BMI; Body mass index, AMH; Anti-mullerian hormone, LH; Luteinizing hormone, FHS; Follicle stimulating hormone and *; P<0.05.
Clinical characteristics of the patients. There is significant difference in AMH, No. of mature oocyte and total rFSH dose (IU) between POR and control groups. Data were analyzed by t test.